Jinarc is a specialist product for which additional training is available prior to prescribing. If you wish to register as a prescriber to receive notification of materials update and yearly training reminders, please visit https://www.jinarctraining.co.uk/. This guide has been developed for prescribers and healthcare professionals (HCPs) involved in the treatment of patients using Jinarc (tolvaptan). This document summarises important information on the potential risk of hepatic toxicity and provides guidance on how to manage this risk. In addition, it provides important information about pregnancy prevention before and during the treatment with Jinarc.

Jinarc is a specialist product for which additional training is available prior to prescribing. If you wish to register as a prescriber to receive notification of materials update and yearly training reminders, please visit https://www.jinarctraining.co.uk/. This material is provided by Otsuka Pharmaceuticals as a licence requirement for this medicine and forms part of the Risk Management Plan.

Jinarc is a specialist product for which additional training is available prior to prescribing. If you wish to register as a prescriber to receive notification of materials update and yearly training reminders, please visit https://www.jinarctraining.co.uk/. This patient alert card should be used by patients who have been prescribed medicines containing tolvaptan and should carry with them at all times when taking this medicine. This card contains important safety information that patient needs to be aware of before, during, and after treatment with Jinarc (tolvaptan).

Jinarc is a specialist product for which additional training is available prior to prescribing. If you wish to register as a prescriber to receive notification of materials update and yearly training reminders, please visit https://www.jinarctraining.co.uk/. The guide should be provided to patients by the prescribing physician and includes a description of the risks of treatment, guidance on what to do in the event of risks occurring and an overview of treatment monitoring.